INVESTOR ALERT: ZBIO Under Investigation by Pomerantz Law

Company Overview and Recent Developments

Zenas BioPharma (NASDAQ: ZBIO) is a clinical-stage biopharmaceutical company focusing on autoimmune diseases. The company went public in September 2024, raising gross proceeds of about $225 million at an IPO price of $17 per share (www.nasdaq.com). Since then, Zenas advanced its lead drug obexelimab (a bispecific antibody targeting CD19 and FcγRIIb) through Phase 3 trials in IgG4-Related Disease (IgG4-RD) and Phase 2 trials in Relapsing Multiple Sclerosis (RMS). In early January 2026, Zenas announced that obexelimab met the primary endpoint in IgG4-RD, showing a 56% reduction in risk of disease flares versus placebo (www.globenewswire.com). Despite management describing these results as “positive,” subsequent analysis revealed that the efficacy was significantly lower than a competing therapy’s, casting doubt on obexelimab’s commercial prospects (www.prnewswire.com) (www.biopharmadive.com). Following this news, ZBIO’s stock plunged over 50% in one day (www.prnewswire.com), wiping out hundreds of millions of dollars in market value (www.biopharmadive.com). The steep selloff and concerns of misleading optimism have prompted Pomerantz LLP to investigate potential securities fraud on behalf of ZBIO investors (www.prnewswire.com) (www.prnewswire.com). This report will examine Zenas’s financial profile – including its dividend policy, leverage, valuation, and key risks – in light of these developments.

Dividend Policy & Shareholder Returns

Zenas BioPharma is a development-stage biotech with no approved products or earnings, and it has never paid dividends. In fact, the company explicitly states it does not anticipate paying any cash dividends in the foreseeable future, preferring to reinvest any future earnings into R&D and growth (www.sec.gov). As a result, ZBIO offers a 0% dividend yield, and investors’ returns hinge entirely on stock price appreciation (or depreciation). With no positive Funds From Operations (FFO) or Adjusted FFO (AFFO) – metrics relevant for profitable, cash-generative companies – traditional income measures are not applicable here. Zenas’s “shareholder yield” is effectively negative, considering ongoing dilution (through equity financings) and share price declines. Any potential future return will depend on successful product commercialization, which is uncertain. For now, capital appreciation remains the sole source of potential gain for ZBIO investors (www.sec.gov).

Leverage, Liquidity, and Debt Maturities

Zenas has financed its ambitious drug pipeline primarily via equity raises and non-traditional financings rather than conventional debt. The company’s debt-to-equity ratio stands at ~0.37, reflecting relatively modest liabilities relative to equity capital (www.defenseworld.net). Importantly, Zenas has not incurred significant traditional debt – it carries no term loans or bonds with imminent maturities. Instead, the firm tapped alternative funding sources:

- Royalty Financing: In September 2025, Zenas entered a Revenue Participation Agreement with Royalty Pharma, receiving an upfront $75 million in exchange for rights to a 5.5% royalty on future obexelimab sales worldwide (www.sec.gov) (www.sec.gov). This deal effectively acts as high-cost debt: the effective interest rate is ~30.7% on the royalty obligation (www.sec.gov). Additional milestone-based tranches (up to a total $300 million) were contemplated, including a $75 million payment conditional on timely success of the IgG4-RD Phase 3 trial (www.sec.gov). It is unclear if this milestone was met by the year-end deadline, given the results were announced January 5, 2026 – any delay risks forfeiting that infusion of cash.

- Regional Licensing Deals: Zenas raised non-dilutive capital through partnerships. In August 2023, it licensed obexelimab rights in parts of Asia-Pacific to Bristol Myers Squibb (BMS) for a $50 million upfront fee, plus up to ~$150 million in milestones and tiered royalties (www.sec.gov). Zenas also out-licensed a thyroid eye disease program (ZB001) to Zai Lab for Greater China and a preclinical asset (ZB005) to Tenacia Biotech, garnering a combined ~$15 million in upfronts (total from partnerships was ~$65M) (www.sec.gov). These deals provide cash but also commit Zenas to collaborative obligations and regional profit-sharing rather than fixed debt repayments.

- Equity Financings: In addition to its IPO, Zenas did a $120 million PIPE (private investment) in October 2025 (www.sec.gov). Thanks to these cash inflows, the company reported cash and investments of ~$301.6 million as of Sept 30, 2025 (before the PIPE funding) (www.sec.gov). Pro forma for the PIPE, Zenas had roughly $420+ million in liquidity entering 2026, which management projected would fund operations into Q4 2026 (www.sec.gov).

Overall, Zenas’s leverage is low in a traditional sense – there are no looming principal repayments – but the royalty financing is a substantial obligation that will siphon off future revenue at a high effective cost (www.sec.gov). There are also restrictive covenants: for instance, the Royalty Pharma agreement limits Zenas’s ability to incur new debt or out-license the obexelimab asset without consent (www.sec.gov). With current ratios around 5.7 and a large cash cushion (www.defenseworld.net), short-term liquidity appears solid. However, sustaining the pipeline long term will require either commercial success or more capital raises, as detailed next.

Financial Performance and Coverage Ratios

As an R&D-stage biotech, Zenas generates no product revenue and runs at a substantial net loss. The company has “not generated any revenue from product sales since inception” (www.sec.gov) – any reported revenue has been from licensing or collaboration accounting. Meanwhile, operating expenses have steadily increased with late-stage trials. In the first half of 2025, Zenas’s net loss was $85.8 million, wider than the $65.8 million loss in the prior-year period (www.sec.gov) (www.sec.gov). For Q3 2025 alone, the loss was over $50 million (www.sec.gov). Cumulatively, the company has an accumulated deficit of $524.7 million as of September 30, 2025 (www.sec.gov), underscoring the heavy historical cash burn.

Given these losses, coverage ratios that measure ability to service debt (like interest coverage or fixed-charge coverage) are not meaningful – Zenas has no positive EBITDA or FFO to cover interest (and, indeed, has minimal interest expense on its books). The aforementioned Royalty Pharma obligation accrues interest implicitly, but payments will only occur if obexelimab generates sales (www.sec.gov). In effect, Zenas is financing its operations with equity and asset monetizations, so the primary coverage concern is cash runway. With ~$420M on hand post-Pipe, management believes it can fund operations through late 2026 (www.sec.gov). However, if obexelimab’s commercial outlook remains weak, Zenas may face a funding gap by 2027, as ongoing Phase 3 trials (like in progressive MS) will continue to consume cash. Investors should monitor whether further cost cuts, partnerships, or dilutive equity raises become necessary to extend the runway.

Valuation and Analyst Outlook

Traditional valuation metrics for ZBIO are challenging due to negative earnings and zero sales. The stock’s price-to-earnings (P/E) ratio is effectively meaningless (listed as around -2.3) because earnings per share are deeply negative (www.defenseworld.net). Price-to-FFO metrics don’t apply with no operational funds flow. For lack of fundamentals, the market has been valuing Zenas on its pipeline prospects and cash balance. Prior to the IgG4 trial results, optimistic expectations for obexelimab and the MS indication drove ZBIO to a 52-week high of $44.60 (over a $2.3 billion market cap) (www.defenseworld.net). At that peak, the stock traded at a hefty premium to its ~$350M book value, implying investors were pricing in blockbuster potential.

After the January 2026 crash, ZBIO shares hover near $15–$16, equating to a market capitalization around $900 million (www.defenseworld.net). Backing out an estimated ~$400M in net cash, the enterprise value (EV) of roughly $500 million represents the market’s current assessment of Zenas’s pipeline. This EV reflects sharply reduced expectations for obexelimab in IgG4-RD, partially offset by remaining optimism for other indications like MS. Notably, Wall Street analysts have rapidly reset their outlook post-data: Morgan Stanley downgraded ZBIO from Overweight to Equal-Weight and slashed its price target to $19 right after the trial news (www.defenseworld.net). This is a stark drop from pre-result consensus – as of late December, six analysts rated Zenas a “Buy” with a $43.71 average target (www.defenseworld.net) (targets ranged up to $52 from Jefferies (www.defenseworld.net)). Clearly, the perceived valuation has been cut by more than half given obexelimab’s underperformance.

Looking at comparables, other small biotech companies with a Phase 3 autoimmune drug often trade at EVs of a few hundred million dollars unless clear clinical superiority is shown. In Zenas’s case, competition from Amgen’s Uplizna in IgG4-RD (discussed below) severely undercuts the pricing power and market share obexelimab might achieve, warranting a much lower valuation. The price-to-book ratio now is roughly 2.0x (with ~$450M equity on a $900M market cap) – still not cheap for a pre-revenue firm, but considerably less frothy than before. No dividend yield, negative earnings, and high R&D uncertainty make ZBIO’s valuation highly speculative. Future adjustments to valuation will hinge on upcoming milestones: for example, any regulatory approval in IgG4-RD (despite its limitations), progress in MS trials, or new partnerships could shift sentiment.

Key Risks and Red Flags

1. Efficacy and Commercial Viability of Obexelimab: The biggest red flag is that Zenas’s lead asset may be clinically inferior to an existing competitor. While obexelimab hit its primary endpoint in IgG4-RD, reducing flare risk by 56%, a recently approved rival therapy (Amgen’s Uplizna) achieved an 87% risk reduction in its trial (www.biopharmadive.com) (www.clinicaltrialsarena.com). This stark gap suggests obexelimab might “fall short of the threshold for a commercially viable drug,” as one analyst put it (www.biopharmadive.com). In other words, physicians and payers may favor Uplizna (or even off-label Rituxan) given their greater efficacy, leaving obexelimab with a narrow market niche. Zenas’s CEO himself acknowledged being “disappointed that the hazard ratio doesn’t hit a number that many people were hoping for” (www.globenewswire.com). This admission on the January 6 investor call underscores that the company’s upbeat press release may have obscured important context. The Pomerantz law investigation is examining whether management’s characterization of the results as “positive” misled investors about the drug’s true prospects (www.prnewswire.com). A drug that is technically successful in trials but unlikely to compete well commercially poses a major risk to Zenas’s future revenue and credibility.

2. Regulatory and Development Uncertainty: Even if obexelimab is moderately effective, approval is not guaranteed. The Phase 3 INDIGO trial, while meeting endpoints, has not yet released full data to the public or regulators. The FDA and EMA will scrutinize whether the drug’s benefit-risk profile warrants approval when existing therapies (steroids, B-cell depletors) are available off-label. Any need for an additional confirmatory trial, or a requirement to demonstrate superiority over Uplizna, could delay or derail approval. Moreover, obexelimab’s strategy of B-cell inhibition (versus depletion) is novel; unforeseen safety signals could emerge in extended follow-up. Zenas plans to file for FDA approval (BLA) in Q2 2026 (www.globenewswire.com), but regulatory outcomes remain a risk, especially if efficacy is deemed marginal relative to the standard of care.

3. Financial Sustainability and Dilution: Zenas’s cash burn is high and mounting – over $50 million per quarter in recent periods (www.sec.gov) – and the company will likely consume its cash reserves by late 2026 without substantial revenue or new funding (www.sec.gov). If obexelimab’s IgG4-RD opportunity is limited, Zenas may not see any product revenue for years (the MS program is still in Phase 3 and even if successful, an approval is at least 2–3 years out). This raises the probability of further dilutive stock offerings or debt/royalty financings to bridge the gap. Notably, Zenas has already encumbered future obexelimab sales with a 5.5% royalty to Royalty Pharma (www.sec.gov), which could complicate new financing or partnership negotiations (a potential partner might be deterred by that royalty overhang). If market sentiment remains poor, raising equity at the current low share price would significantly dilute existing shareholders. Failing to secure capital could force Zenas to delay or cut R&D programs (www.sec.gov) (www.sec.gov), jeopardizing its pipeline’s value.

4. Pipeline Concentration and Clinical Risk: Zenas is essentially a two-product company – obexelimab and orelabrutinib – with a few earlier-stage assets. The heavy reliance on obexelimab means the above issues in IgG4-RD reverberate company-wide. The next major value driver, orelabrutinib (a BTK inhibitor for progressive MS), comes with its own risks: BTK inhibitors are an unproven mechanism in MS, and competing trials from Biogen and others have had mixed results. Zenas only licensed orelabrutinib in mid-2025 (www.biospace.com) and has just begun Phase 3 trials in Primary Progressive MS (PPMS) and soon Secondary Progressive MS (www.biospace.com). These trials will be lengthy and expensive, and their outcomes uncertain in a challenging indication. Any setback – clinical failure, safety issue, or competitor success (e.g., another BTK inhibitor beating them to market) – would leave Zenas with little else to fall back on. The concentration risk is high: if obexelimab falters and orelabrutinib disappoints, Zenas has no approved products and scant revenue options, which could be catastrophic for the stock.

5. Legal and Governance Overhang: The fact that multiple law firms (including Pomerantz) are soliciting shareholders for a class-action suggests a risk of distraction, reputational damage, or even potential liability. These investigations often claim that executives overstated prospects or withheld material info. For instance, if it’s proven that management knew Uplizna’s 87% efficacy benchmark and failed to temper investor expectations, there could be grounds for a lawsuit. While such cases can take years and may ultimately be dismissed or settled (often covered by D&O insurance), they present a headline risk. Internally, management’s credibility with investors has likely been dented by the handling of the trial results. Trust is critical in biotech, where companies frequently raise capital on the promise of future results – a credibility gap could weigh on Zenas’s stock price until management proves more transparency or delivers an unequivocal win.

Open Questions and Considerations for Investors

- Will obexelimab find a market niche? Assuming obexelimab secures regulatory approval in IgG4-RD, can Zenas commercialize it successfully given Uplizna’s superior efficacy (www.biopharmadive.com)? Management highlights certain advantages – obexelimab is given via self-administered subcutaneous injections (potentially more convenient than Uplizna’s IV infusions) and works via B-cell inhibition, which might allow pausing for vaccinations or reduce certain side effects (www.globenewswire.com). The Phase 3 data also indicated fewer serious infections on obexelimab vs placebo (www.biospace.com) (www.clinicaltrialsarena.com). Could these practical benefits persuade physicians to use obexelimab in patients who can’t tolerate B-cell depletion? Or will Uplizna and rituximab remain the go-to treatments? How payers approach coverage – possibly requiring failure on Uplizna first – is another unknown. Investors should watch for full INDIGO trial data (to be presented at a medical conference) for clues on subpopulation efficacy, and whether Zenas pursues combination therapy or other strategies to differentiate obexelimab in IgG4-RD.

- What is the plan for obexelimab in other indications? Zenas had been positioning obexelimab as a pipeline-in-a-product for B-cell mediated diseases. Aside from IgG4-RD, obexelimab showed very strong Phase 2 results in relapsing MS (95% reduction in new brain lesions) (www.techfocusasia.com), and the company was conducting a Phase 2 trial in Systemic Lupus Erythematosus (SLE) (the “SunStone” trial) (investors.zenasbio.com). Can the MS program proceed given the IgG4-RD setback? Positive MS data initially sent the stock up over 30% (www.clinicaltrialsarena.com), implying significant investor interest. However, Phase 3 in MS would require large trials and partnership or substantial funding. Will Zenas seek a big pharma partner to co-develop obexelimab in MS or other autoimmune diseases? If management pivots resources to MS (a larger market than IgG4-RD), that could reinvigorate the bull case – but it’s a long road to approval, and competition (e.g., anti-CD20s like Ocrevus, BTK inhibitors in development) remains fierce in MS too. Similarly, any readout from the SLE trial could be a catalyst or point of discontinuation. Investors should clarify with management on upcoming data milestones beyond IgG4-RD and how they’ll be funded.

- How will Zenas shore up its finances? With roughly 18–24 months of cash runway left (www.sec.gov), Zenas will need to address its funding well before the money runs out. Can the company unlock the next $75M+ tranche from Royalty Pharma? That likely required hitting the IgG4-RD trial milestone by end of 2025 (www.sec.gov); if that milestone wasn’t met in time (due to the slight delay into January 2026), Zenas might lose out on a helpful infusion. If obexelimab’s prospects are now dimmer, raising equity at acceptable terms could be challenging – will management wait for a stock rebound (for example, on any partnership news) or be forced to do a highly dilutive financing at these depressed prices? Another approach could be cost-cutting or prioritizing programs, but trimming R&D too much could stunt the pipeline’s progress. The possibility of mergers & acquisitions (M&A) should also be considered: might a larger pharma acquire Zenas for its MS asset or other pipeline pieces, given the low valuation? Such outcomes are speculative, but investors should keep an eye on strategic moves. The next few quarters’ earnings calls should give insight into Zenas’s financing strategy and whether they can extend their cash runway without crushing existing shareholders.

- Outcome of the legal investigation? While class-action probes are common after stock drops, it’s worth asking: did Zenas’s management communicate appropriately? Open questions include whether any company statements prior to January 5 overstated obexelimab’s likely impact or omitted known competitive context (like Uplizna’s data). Also, were any insiders selling stock during the late-2025 run-up to $44? (So far, one director bought shares in late 2025 at $19 (www.defenseworld.net), which might support the company’s good faith, but we haven’t seen reports of insider sales before the crash.) The resolution of Pomerantz’s investigation (or any class action) could take a long time and may simply result in a settlement. However, investors will be looking for management to rebuild trust. Enhanced transparency – for example, providing clear comparisons to standard-of-care in future press releases – would be a welcome step. The legal overhang is an uncertainty; any evidence of wrongdoing could further damage the stock, while a quick dismissal could remove a cloud.

In sum, ZBIO faces a pivotal period. The investor optimism of 2025 has flipped to skepticism after obexelimab’s lukewarm Phase 3 showing. The stock’s collapse and legal scrutiny highlight the importance of realistic communication and competitive analysis in biotech. Going forward, Zenas BioPharma must navigate commercial challenges for obexelimab, execute costly late-stage trials for orelabrutinib, and likely secure additional funding – all under the watchful eyes of wary investors. This “Investor Alert” underscores both the significant risks in ZBIO and the potential for volatility as new data emerge. Cautious due diligence is warranted, as the company’s fortunes may hinge on its responses to the open questions above and its ability to deliver truly differentiated therapies in an increasingly competitive landscape.

Sources: Zenas BioPharma SEC filings and press releases; Pomerantz LLP notices; BioPharmaDive and ClinicalTrialsArena analysis; company investor relations materials. (www.sec.gov) (www.prnewswire.com) (www.biopharmadive.com) (www.clinicaltrialsarena.com) (www.sec.gov)